Advances in anti-arthritic agents. 24-25 January 2000, London, UK

This meeting provided an excellent overview of the field of arthritis, although most of the drugs mentioned were designed to treat rheumatoid arthritis. There was an air of excitement surrounding the event because, after a substantial period of dormancy in clinical rheumatology, there are now many promising new treatments emerging, which, it is hoped, will greatly improve the quality of life for numerous arthritis sufferers. Speakers covered topics as diverse as care for sufferers, impact of the disease, status of current treatments, and approaches for the future. The majority of the presentations were drug-oriented; the speaker generally gave a summary of their company's arthritis research program and then followed this with a case study of its lead compound.